In 500 patients with previously treated metastatic pancreatic cancer, daraxonrasib vs investigator's-choice chemotherapy gave median overall survival of 13.2 vs 6.6 months in the RAS G12 population (HR 0.40); median PFS 7.3 vs 3.5 months (HR 0.45). Grade ≥3 events 61.8% vs 69.6%.
RCTn = 500
O'Reilly et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer